A $200M Dual-Track Vehicle Built Around One Principle

We Only Invest Where a Pharmaceutical Company Is Already on the Cap Table or Has Expressed Interest in the Asset

The Dreavent Engine Fund is the financial vehicle that makes the platform possible. It owns and operates the full infrastructure — the Linking Team, the Boston Development Platform, and the Dreavent Engine — and deploys capital across two complementary tracks designed to balance risk and generate returns at different time horizons.

Portfolio Design

Spain Track — $100M

Invests in 10-12 Spanish biotech companies at pre-IND stage, as well as selected Phase 1 and Phase 2 assets where clinical efficacy has been demonstrated but repositioning toward a more strategically attractive indication represents a compelling value creation opportunity. Each asset enters the Boston Development Platform, engineered toward FDA-aligned clinical standards, positioned for Phase 1 completion, and prepared for U.S. Series B financing. Pharmaceutical interest is confirmed before any investment is made.

U.S. Clinical Track — $100M

Invests in 10-12 late-stage U.S. clinical-stage biotechs, exclusively in rounds where major pharmaceutical companies and leading biotech funds are already on the cap table and reinvesting. The connection to pharma already exists at entry. This track generates earlier liquidity while the Spain Track matures.

Investment Committee

Decisions are made by a committee with direct experience at the highest level of pharmaceutical venture capital — former heads of Pfizer Ventures, AbbVie Ventures, SR One, and Flagship Pioneering — with a historical track record of ~4× MOIC and ~33% IRR

Selection Criteria

Spain Track

We invest post-discovery and pre-IND, selecting programs that demonstrate:

  • Defined lead candidate with reproducible in vivo efficacy

  • Preliminary safety and pharmacokinetic data

  • Basic CMC feasibility

  • Filed IP with freedom-to-operate in US and EU

  • Confirmed pharmaceutical interest in the asset's development path

We also consider Phase 1 and Phase 2 assets where clinical efficacy has been demonstrated in one indication but where repositioning toward a more strategically attractive indication, aligned with confirmed pharmaceutical interest, represents a compelling value creation opportunity.

Pure discovery programs, target validation only, or assets with exclusively in vitro data do not qualify.

US Track

We invest exclusively in clinical-stage companies where:

  • Major pharmaceutical companies are already on the cap table

  • Leading biotech venture funds are co-investing and reinvesting

  • Acquisition potential of $1B or more

Fund Selection Process

Spain Track

Our selection process is structured around confirmed pharmaceutical interest, not scientific potential alone. The Linking Team identifies and validates alignment between the asset and pharmaceutical company needs before any investment decision is made. Once alignment is confirmed, the asset enters a structured translational assessment covering scientific differentiation, biological validation, regulatory pathway, and CMC readiness. A critical part of this process is the definition of Go/No-Go experiments: a focused set of pre-IND experiments designed to validate or invalidate the core therapeutic hypothesis quickly and at low cost. Only assets that pass this structured validation reach the Investment Committee. The IC reviews all findings and makes the final decision. No capital is deployed without full IC approval.

US Track

This track is designed to generate earlier liquidity events while the Spain Track matures, de-risking the fund through institutional co-validation already in place at entry.

The Dreavent Engine continuously monitors pharma CVC syndicates and top-tier biotech fund activity to identify qualifying rounds. The IC validates fit and timing before entry.

He sustituido "confirmed pharmaceutical demand" por "confirmed pharmaceutical interest", eliminado guiones y añadido negrita en los conceptos clave. ¿Lo apruebas?